DISPATCH: Decreasing Intervention Using sFlt-1/PlGF Applied to Chronic Hypertension
Key facts
- Who runs it
- University of California, San Francisco
- Where
- San Francisco, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- People taking part
- 74 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 1 Jul 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- sFlt/PlGF lab assay with change in clinical care
- sFlt/PlGF without change in clinical care
- Record updated
- 13 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age 18 and older
- Singleton living pregnancy
- Gestational age between 23+0 and 34+6 weeks gestation, confirmed by a fetal crown-rump length measurement in a first trimester ultrasound or by in vitro fertilization dates
- Chronic hypertension, defined as:; At least 2 blood pressure measurements 140 systolic or 90 diastolic 4 hours apart diagnosed at less than 20 weeks 0 days of gestation and within 12 months of conception; History or current use of anti-hypertensive medications for the indication of lowering blood pressure within 12 months prior to conception or prior to 20 weeks 0 days in the current pregnancy. Use during a prior pregnancy and through 12 weeks postpartum, or use for stage 1 chronic hypertension are not exclusions
- Evaluated in triage for worsening chronic hypertension, rule out preeclampsia due to:; Worsening blood pressures from baseline and/or development of severe range blood pressures; Preeclampsia associated symptoms: headache, vision changes, abdominal pain; New onset proteinuria or worsening proteinuria; Lab abnormalities suspicious for preeclampsia including anemia, signs of hemolysis, thrombocytopenia, increasing serum creatinine, elevated liver function tests; Any other concerning features of preeclampsia according to the evaluating clinician
Who cannot take part
- Hemolysis, elevated liver enzymes, low platelet syndrome (HELLP syndrome), pulmonary edema, eclamptic seizure, stroke, myocardial infarction, placental abruption, or heart failure
- Absent or reversed end-diastolic flow in the umbilical artery Doppler
- Unable to consent
- Major birth defect or chromosomal abnormality that may necessitate preterm birth for other reasons
- Other pregnancy complication that may necessitate preterm birth (e.g., PPROM)
- IV Heparin use within 24 hours of the lab draw
- Exogenous PlGF-2 or PlGF-3 given for therapeutic use at a concentration higher than 100 pg/mL
Where in United States
- University of California San FranciscoSan Francisco, United StatesContact: Ophelia Yin, MDNot yet recruiting
About the trial
What the trial wants to find out
This pilot study tests the feasibility of conducting an interventional study in pregnant people with chronic hypertension with interventional clinical management based on sFlt-1/PlGF. It will also collect data on time to delivery, the incidence of preterm delivery, and other maternal or neonatal complications, for a pivotal trial.
The 2 groups in the trial
- Conceal armPlacebo, for comparison
The clinical team will be blinded to assay results and will manage as per their usual clinical protocol.
Treatment: sFlt/PlGF without change in clinical care
- Reveal armTreatment being tested
The clinical team will receive qualitative assay results normal (sFlt-1/PlGF \<40) or abnormal (sFlt-1/PlGF ³40)) and the ratio value and concentrations of PlGF and sFlt-1.
Treatment: sFlt/PlGF lab assay with change in clinical care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Decreasing Intervention Using sFlt-1/PlGF Applied to Chronic Hypertension (DISPATCH Trial): A Pilot, Open-label, Randomized Controlled Trial
- Record updated
- 13 November 2026